GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Tax Provision

Sandoz Group AG (FRA:D8Y0) Tax Provision : €13 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Tax Provision?

Sandoz Group AG's tax provision for the six months ended in Dec. 2024 was €62 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was €13 Mil.


Sandoz Group AG Tax Provision Historical Data

The historical data trend for Sandoz Group AG's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Tax Provision Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24
Tax Provision
-237.89 -45.85 11.46

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Tax Provision - -116.30 69.69 -49.24 62.08

Sandoz Group AG Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG Business Description

Traded in Other Exchanges
Address
Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines